Rallybio develops monoclonal antibodies targeting rare diseases, focusing on conditions like Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT). The company aims to provide effective treatment options that have been historically unavailable for patients suffering from these debilitating conditions.
Funding
$6.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
JJFounders
Product
Problem
Treatments for rare diseases often lag behind patient needs, leaving many conditions with limited or no effective therapies. This is particularly true for conditions like Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), where treatment options have historically been unavailable.
Solution
Rallybio is developing monoclonal antibodies to address unmet needs in rare diseases, with a focus on FNAIT. Their approach aims to provide targeted and effective treatments for patients suffering from these debilitating conditions. By developing novel therapies, Rallybio seeks to significantly improve outcomes for individuals with rare diseases.
Target Audience
The primary target audience includes patients suffering from rare diseases, particularly FNAIT, and the healthcare providers who treat them.
Features
- Development of anti-HPA-1a monoclonal antibody for the prevention of FNAIT.
- Focus on advancing clinical and preclinical programs for rare disease treatments.
- Identification of new targets and product candidates through global searches.